# The Hemophilia Inhibitor Eradication Trial

> **NCT04303572** · PHASE3 · TERMINATED · sponsor: **Margaret Ragni** · enrollment: 1 (actual)

## Conditions studied

- Hemophilia A With Inhibitor

## Interventions

- **DRUG:** Eloctate ITI
- **DRUG:** Emicizumab

## Key facts

- **NCT ID:** NCT04303572
- **Lead sponsor:** Margaret Ragni
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-11-01
- **Primary completion:** 2022-06-27
- **Final completion:** 2022-06-27
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** The INHIBIT Trials IDSMB, in a letter dated 05-18-22, recommended, given the slow enrollment, that the INHIBIT Trials be discontinued due to futility.
- **Last updated:** 2023-02-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04303572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04303572, "The Hemophilia Inhibitor Eradication Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04303572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*